Shares of Glaukos Corporation (GKOS) surged 18.23% on Wednesday following the release of the company's impressive third-quarter 2025 financial results and raised guidance. The medical device maker specializing in ophthalmic technologies significantly outperformed market expectations, demonstrating robust growth and improved profitability.

For the third quarter, Glaukos reported record net sales of $133.5 million, marking a 38% year-over-year increase and surpassing analysts' expectations of $122.5 million. The company's adjusted earnings per share came in at -$0.16, beating the consensus estimate of -$0.26. Notably, U.S. glaucoma sales showed exceptional strength, growing 57% year-over-year to $80.8 million. The company's gross margin improved to approximately 78%, with a non-GAAP gross margin of about 84%.

Investors were particularly enthused by Glaukos's forward-looking projections. The company raised its 2025 net sales guidance to a range of $490 million to $495 million, up from the previous estimate of $480 million to $486 million. Moreover, Glaukos introduced its preliminary net sales outlook for 2026, forecasting sales between $600 million and $620 million, signaling confidence in sustained long-term growth. CEO Thomas Burns attributed the strong momentum to successful execution of strategic plans and advancement of novel, dropless platform technologies.

The positive results and outlook have reinforced analysts' confidence in Glaukos. The current average analyst rating on the shares is "buy," with 14 "strong buy" or "buy" recommendations, 1 "hold," and 1 "sell" or "strong sell." Wall Street's median 12-month price target for Glaukos is $115.00, representing a potential upside of approximately 32.4% from its previous closing price.